Sonnet BioTherapeutics Holdings, Inc. $SONN Stock Soar After FDA Approval
Sonnet BioTherapeutics Holdings, Inc. SONN Stock Update:
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors. “The FDA’s acceptance of the IND for SON-1010 is an important milestone in the development of our lead FHAB asset, signifying the evolution of Sonnet into a clinical biopharmaceutical company,” said Pankaj Mohan, Ph.D., Founder and Chief Executive Officer. “We are excited about the progress we have made with our FHAB platform, which we believe will set the stage for improved efficacy of monospecific and bispecific cytokines, each differentiated by tumor targeting and retention in the tumor microenvironment.”
Wonder which online trading app would be easy and rewarding, also let you trade us pre market, day trading, Nasdaq index futures, and many more with an advanced trading chart? Join Moomoo and get up to 5 free stocks worth from $3 up to $3,500 each.
SIGN UP TO THIS SITE FOR FREE – Receive Daily Short Squeeze Email Updates
Sponsered: CapitalOne Silver Credit Card is giving a $200 sign-up bonus after you spend $500 in the first 3 months. This card is the most recommended for everyday spending, Earn unlimited 1.5% cash back on every purchase, with no annual fees. If you think you will spend $500 in 3 months, this might be a great card for you to start, and get that $200 sign-up bonus.